Norway · Delayed Price · Currency is NOK Zelluna ASA Earnings Call Transcripts
Fiscal Year 2026
-
A novel off-the-shelf cell therapy platform is advancing to clinical trials for solid tumors, targeting MAGE-A4 with a dual TCR-NK mechanism. The phase I study will focus on safety and proof of mechanism, with initial data expected from mid-2026.
Fiscal Year 2025
-
Raised NOK 58 million, extending cash runway into Q1 2027, and advanced ZIMA-401 to first-in-human trials with strong preclinical data. Discontinued non-core programs to focus on scalable TCR-NK platform, with initial clinical data expected mid-2026.
-
Raised NOK 58 million, extending funding into Q1 2027, and advanced the lead TCR-NK program toward clinical trials with first patient data expected mid-2026. Positive regulatory feedback and pipeline expansion position the company for potential value inflection.
-
On track for IND/CTA filing for lead program ZI-MA4-1 in H2 2025, with first human data expected H1 2026. Cash position of NOK 76 million provides runway into Q2 2026, as R&D and transaction costs impact short-term results. Strong sector momentum for off-the-shelf cell therapies.
-
Achieved Oslo Stock Exchange listing and completed a business combination, securing NOK 135 million in cash and a financial runway through Q2 2026. Advanced scalable TCR-NK manufacturing, with clinical trial application planned for later this year and initial human data expected in 2026.
Fiscal Year 2024
-
Ultimovacs and Zelluna Immunotherapy are merging to form Zelluna ASA, with a NOK 51.7 million private placement extending the financial runway through Q2 2026. Q4 2024 saw significant impairments, workforce reductions, and a focus on advancing the TCR-NK platform toward clinical milestones.
-
The merger combines complementary strengths in cell therapy innovation and clinical execution, supported by strong shareholder backing and a robust IP position. The deal includes a private placement, provides funding through Q2 2026, and targets leadership in the solid tumor market.
-
Q3 2024 saw negative FOCUS trial results and halted LUNVACC enrollment, but DOVACC trial enrollment remains strong with data expected in H1 2025. Cash runway now extends to Q1 2026 due to cost-saving measures, and updates on the drug conjugation platform are due by year-end.
-
Q2 2024 saw negative trial results for UV1 in key indications, but ongoing DOVACC and LUNGVAC trials continue with cash preservation extending runway to Q4 2025. A novel drug conjugation platform is in preclinical development, with updates expected by year-end.